Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Participate at William Blair Biotech Focus Conference 2022
July 01, 2022 07:00 ET | FibroGen, Inc.
SAN FRANCISCO, July 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the William...
Cornerstone_Pharma_Logo_V (1).png
Cornerstone Pharmaceuticals to Present Pancreatic Cancer Data on CPI-613® (Devimistat) From Its Open-Label Phase 1 Study at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022
June 27, 2022 08:00 ET | Cornerstone Pharmaceuticals, Inc.
CRANBURY, N.J., June 27, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael...
Cend_ID_Color.jpg
Cend Therapeutics Announces First Patient Treated in Phase 2b Trial of CEND-1 led by Australasian Gastro-Intestinal Trials Group
June 09, 2022 08:05 ET | Cend Therapeutics Inc.
SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) -- Cend Therapeutics, Inc. (“Cend”) today announced that the first patient has been treated in the Phase 2b study of CEND-1, Cend’s lead investigational...
Cornerstone_Pharma_Logo_V (1).png
Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
June 01, 2022 08:00 ET | Cornerstone Pharmaceuticals, Inc.
Cranbury, NJ, June 01, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report First Quarter 2022 Financial Results
April 25, 2022 07:00 ET | FibroGen, Inc.
SAN FRANCISCO, April 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2022 financial results on Monday, May 9 after the market close. FibroGen will also...
HCW Logo_Full_Color_600x_JPEG (2).jpg
HCW Biologics’ CEO Hing C. Wong, Ph.D., to be Featured Speaker at the Third Annual International Conference on Cell and Experimental Biology 2022
April 19, 2022 07:33 ET | HCW Biologics, Inc
Preclinical data for lead investigational drug, HCW9218, in treatment of therapy-induced senescence in cancer Debut of preclinical data related to age-associated diseases MIRAMAR, Fla.,...
Global Oncology Nutrition Markets Report 2022-2026 - Ongoing Research and Development Initiatives Fuel Demand for Oncology Nutrition Products
April 15, 2022 08:13 ET | Research and Markets
Dublin, April 15, 2022 (GLOBE NEWSWIRE) -- The "Oncology Nutrition - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Oncology Nutrition...
Black patients more likely to be excluded from pancreatic cancer clinical trials
March 29, 2022 10:32 ET | VCU Massey Cancer Center
RICHMOND, Va., March 29, 2022 (GLOBE NEWSWIRE) -- Clinical trials are responsible for determining the safety and efficacy of drugs, and lead to virtually all standards of cancer care in the U.S....
AIMLogo.jpg
AIM ImmunoTech Announces Abstract Accepted for Presentation at 15th Annual IHPBA World Congress
March 28, 2022 07:35 ET | AIM ImmunoTech Inc.
OCALA, Fla., March 28, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
March 16, 2022 07:05 ET | AIM ImmunoTech Inc.
Data seen to date indicates that Ampligen® (rintatolimod) could be a potential effective maintenance therapy after systemic chemotherapy in patients with advanced pancreatic cancer In a...